Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Asset Resilience Ratio
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has an Asset Resilience Ratio of 0.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Guangzhou Baiyunshan Pharmaceutical Hold's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Guangzhou Baiyunshan Pharmaceutical Hold total assets.
Liquid Assets Composition Over Time
This chart breaks down Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore GU5 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €4.00 Million | 0.0% |
| Total Liquid Assets | €4.00 Million | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Industry Peers by Asset Resilience Ratio
Compare Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IS:SELEC |
Medical Distribution | 7.12% |
|
Medios AG
XETRA:ILM1 |
Medical Distribution | 0.08% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 4.21% |
Annual Asset Resilience Ratio for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | €4.00 Million ≈ $4.68 Million |
€84.51 Billion ≈ $98.80 Billion |
0.00pp |
| 2023-12-31 | 0.01% | €4.00 Million ≈ $4.68 Million |
€78.59 Billion ≈ $91.88 Billion |
-0.07pp |
| 2022-12-31 | 0.08% | €56.87 Million ≈ $66.49 Million |
€74.67 Billion ≈ $87.29 Billion |
+0.07pp |
| 2020-12-31 | 0.01% | €4.00 Million ≈ $4.68 Million |
€59.76 Billion ≈ $69.87 Billion |
-2.99pp |
| 2018-12-31 | 3.00% | €1.54 Billion ≈ $1.80 Billion |
€51.48 Billion ≈ $60.19 Billion |
+2.98pp |
| 2017-12-31 | 0.02% | €4.88 Million ≈ $5.70 Million |
€28.31 Billion ≈ $33.10 Billion |
-0.01pp |
| 2016-12-31 | 0.02% | €6.03 Million ≈ $7.05 Million |
€25.90 Billion ≈ $30.28 Billion |
-0.25pp |
| 2015-12-31 | 0.27% | €43.19 Million ≈ $50.49 Million |
€15.87 Billion ≈ $18.55 Billion |
-- |
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, develo… Read more